Arriving in the landscape of excess body fat management, retatrutide represents a different approach. Different from many existing medications, retatrutide operates as a double agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) binding sites. This concurrent activation promotes several helpful